• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

术前总胆汁酸可作为可手术切除胆道癌患者的预后生物标志物。

Preoperative total bile acid can be used as a prognostic biomarker in patients with operable biliary tract cancers.

作者信息

Fan Shanshan, Zhao Kexin, Lei Jiabao, Ge Yang

机构信息

Department of Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China.

The Third Clinical School of Medicine, Capital Medical University, Beijing, China.

出版信息

Discov Oncol. 2025 May 8;16(1):696. doi: 10.1007/s12672-025-02527-x.

DOI:10.1007/s12672-025-02527-x
PMID:40338467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12061807/
Abstract

BACKGROUND

Biliary tract cancers (BTCs) are highly invasive malignancies with poor prognoses. However, reliable biomarkers for survival prediction remain lacking. Notably, abnormal lipid metabolism has elicited increasing interest in digestive tract tumors, with the liver playing an important role in lipid metabolism.

OBJECTIVE

To explore the relationship between hepatic lipid metabolism-related indicators, assessed through routine clinical biochemical testing and survival prognosis in patients with BTCs.

METHODS

Overall, 109 patients with a pathological diagnosis of BTC from 2017 to 2023 were included in this study. Univariate and multivariate Cox regression analyses were performed using R Studio software, and survival curves were plotted.

RESULTS

Univariate analysis revealed that tumor location and preoperative total bile acid (TBA), carcinoembryonic antigen, cancer antigen (CA)125, and CA19-9 levels were correlated with patient survival (P < 0.05). Multivariate Cox regression analysis identified increased TBA level [hazard ratio (HR) = 0.445, P = 0.004] as an independent prognostic factor for longer survival. Conversely, tumor location [intrahepatic cholangiocarcinoma (iCCA) and/or extrahepatic cholangiocarcinoma (eCCA)] (HR = 2.463, P = 0.036) and increased CA125 and CA19-9 levels (HR = 2.549, P = 0.008 and HR = 2.100, P = 0.019) were independent prognostic factors for shorter survival. Additionally, Kaplan‒Meier survival curves revealed significantly longer survival in patients with increased TBA levels than those in the normal group (P = 0.012). Conversely, patients with iCCA and/or eCCA tumor location and increased CA125 and CA19-9 levels had significantly shorter median survival (P = 0.044, P = 0.013, and P = 0.012, respectively).

CONCLUSION

TBA may be a biomarker for predicting survival in patients with operable BTC, highlighting its clinical significance and application potential.

摘要

背景

胆道癌(BTC)是具有高度侵袭性的恶性肿瘤,预后较差。然而,仍缺乏用于生存预测的可靠生物标志物。值得注意的是,脂质代谢异常在消化道肿瘤中引起了越来越多的关注,肝脏在脂质代谢中起着重要作用。

目的

通过常规临床生化检测评估肝脏脂质代谢相关指标与BTC患者生存预后之间的关系。

方法

本研究共纳入2017年至2023年期间109例经病理诊断为BTC的患者。使用R Studio软件进行单因素和多因素Cox回归分析,并绘制生存曲线。

结果

单因素分析显示,肿瘤位置以及术前总胆汁酸(TBA)、癌胚抗原、癌抗原(CA)125和CA19-9水平与患者生存相关(P<0.05)。多因素Cox回归分析确定TBA水平升高[风险比(HR)=0.445,P=0.004]是生存期延长的独立预后因素。相反,肿瘤位置[肝内胆管癌(iCCA)和/或肝外胆管癌(eCCA)](HR=2.463,P=0.036)以及CA125和CA19-9水平升高(HR=2.549,P=0.008和HR=2.100,P=0.019)是生存期缩短的独立预后因素。此外,Kaplan-Meier生存曲线显示,TBA水平升高的患者生存期明显长于正常组(P=0.012)。相反,iCCA和/或eCCA肿瘤位置以及CA125和CA19-9水平升高的患者中位生存期明显缩短(分别为P=0.044、P=0.013和P=0.012)。

结论

TBA可能是可手术切除的BTC患者生存预测的生物标志物,突出了其临床意义和应用潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc7d/12061807/7edc9cc9febd/12672_2025_2527_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc7d/12061807/f1eefeebe11d/12672_2025_2527_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc7d/12061807/7edc9cc9febd/12672_2025_2527_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc7d/12061807/f1eefeebe11d/12672_2025_2527_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc7d/12061807/7edc9cc9febd/12672_2025_2527_Fig2_HTML.jpg

相似文献

1
Preoperative total bile acid can be used as a prognostic biomarker in patients with operable biliary tract cancers.术前总胆汁酸可作为可手术切除胆道癌患者的预后生物标志物。
Discov Oncol. 2025 May 8;16(1):696. doi: 10.1007/s12672-025-02527-x.
2
Association of preoperative elevated lipoprotein (a) with poor survival in patients with biliary tract cancers.术前脂蛋白(a)升高与胆道癌患者生存不良相关。
Cancer Med. 2024 Jun;13(11):e7331. doi: 10.1002/cam4.7331.
3
[The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].[术前外周血炎症生物标志物对肝内胆管癌根治性切除术后的预后价值]
Zhonghua Zhong Liu Za Zhi. 2022 Nov 23;44(11):1194-1201. doi: 10.3760/cma.j.cn112152-20210324-00265.
4
CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242.CA125:一种优于 CEA、CA19-9 或 CA242 的结直肠癌预后生物标志物。
Tumour Biol. 2021;43(1):57-70. doi: 10.3233/TUB-200069.
5
Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival.新型胆外胆管癌糖类抗原(CA)19-9 分期系统及其对总生存期的影响。
Eur J Surg Oncol. 2020 May;46(5):789-795. doi: 10.1016/j.ejso.2020.01.016. Epub 2020 Jan 11.
6
Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.CA19-9 对胆道癌切除术后患者的预后价值。
Br J Surg. 2017 Feb;104(3):267-277. doi: 10.1002/bjs.10415. Epub 2017 Jan 4.
7
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma.血清肿瘤标志物与阑尾腺癌患者的结局。
JAMA Netw Open. 2024 Feb 5;7(2):e240260. doi: 10.1001/jamanetworkopen.2024.0260.
8
Clinical outcomes and risk stratification in unresectable biliary tract cancers undergoing radiation therapy.不可切除胆道癌患者接受放射治疗的临床结果和风险分层。
Radiat Oncol. 2024 Aug 1;19(1):102. doi: 10.1186/s13014-024-02481-y.
9
The Prognostic Value of the CA19-9/TBIL Ratio in Patients with Biliary Tract Cancers (BTCs): A Retrospective Study.CA19-9/TBIL比值在胆道癌(BTCs)患者中的预后价值:一项回顾性研究
J Oncol. 2021 Feb 23;2021:5829893. doi: 10.1155/2021/5829893. eCollection 2021.
10
Elevated preoperative CA125 levels predicts poor prognosis of hilar cholangiocarcinoma receiving radical surgery.术前CA125水平升高预示着接受根治性手术的肝门部胆管癌预后不良。
Clin Res Hepatol Gastroenterol. 2021 Nov;45(6):101695. doi: 10.1016/j.clinre.2021.101695. Epub 2021 Jun 17.

本文引用的文献

1
Bile Acid Signaling in Metabolic and Inflammatory Diseases and Drug Development.胆汁酸信号在代谢和炎症性疾病及药物研发中的作用
Pharmacol Rev. 2024 Oct 16;76(6):1221-1253. doi: 10.1124/pharmrev.124.000978.
2
Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8 T cell effector functions.肠道微生物群修饰的胆汁酸通过抑制 CD8 T 细胞效应功能促进结直肠癌生长。
Immunity. 2024 Apr 9;57(4):876-889.e11. doi: 10.1016/j.immuni.2024.02.014. Epub 2024 Mar 12.
3
The underappreciated diversity of bile acid modifications.
胆汁酸修饰的被低估的多样性。
Cell. 2024 Mar 28;187(7):1801-1818.e20. doi: 10.1016/j.cell.2024.02.019. Epub 2024 Mar 11.
4
Impaired hepatic lipid metabolism and biomarkers in fatty liver disease.脂肪肝疾病中肝脏脂质代谢受损及生物标志物
Biochimie. 2023 Dec;215:69-74. doi: 10.1016/j.biochi.2023.09.020. Epub 2023 Sep 27.
5
Serum CA125 level as predictors of the efficacy of olaparib maintenance therapy for platinum-sensitive relapsed ovarian cancer.血清 CA125 水平预测奥拉帕利维持治疗铂类敏感复发性卵巢癌的疗效。
J Obstet Gynaecol Res. 2023 Dec;49(12):2883-2888. doi: 10.1111/jog.15798. Epub 2023 Sep 21.
6
Preoperative serum CA125 level is a good prognostic predictor in patients with intrahepatic cholangiocarcinoma after hepatectomy: A single-center retrospective study.术前血清 CA125 水平是肝内胆管细胞癌患者肝切除术后的良好预后预测指标:一项单中心回顾性研究。
Medicine (Baltimore). 2023 Sep 8;102(36):e34839. doi: 10.1097/MD.0000000000034839.
7
The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer.可切除胰腺癌患者术后 CA125 水平的变化规律及其预后意义。
BMC Cancer. 2023 Sep 6;23(1):832. doi: 10.1186/s12885-023-11346-8.
8
The Effectiveness of the Combination of Arterial Infusion Chemotherapy and Radiotherapy for Biliary Tract Cancer: A Prospective Pilot Study.动脉灌注化疗联合放疗治疗胆管癌的疗效:一项前瞻性试点研究。
Cancers (Basel). 2023 May 5;15(9):2616. doi: 10.3390/cancers15092616.
9
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.辅助 S-1 对比观察用于可切除胆管癌(JCOG1202,ASCOT):一项多中心、开放标签、随机、对照、III 期临床试验。
Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4.
10
Elevated bile acid metabolism and microbiome are associated with suppressed cell proliferation and better survival in breast cancer.胆汁酸代谢增强和微生物群与乳腺癌细胞增殖受抑制及更好的生存率相关。
Am J Cancer Res. 2022 Nov 15;12(11):5271-5285. eCollection 2022.